Targeting fibroblast activation protein with chimeric antigen receptor macrophages
Biochemical Pharmacology · 2024-12 · 230 · 116604
DOI: 10.1016/j.bcp.2024.116604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024-12. Verfasst von Yizhi Mao und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Serine Endopeptidases, Receptors, Chimeric Antigen, Macrophages, Endopeptidases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Under the rapid advancement of chimeric antigen receptor T cell (CAR-T) technology, CAR-macrophages (CAR-Ms) are also being developed currently in the pre-clinical stage and have been shown to inhibit tumor growth in several mouse tumor models. Fibroblast activation protein (FAP) is a type II transmembrane serine protease, which is expressed in stromal fibroblasts of over 90 % of common human epithelial cancers and is upregulated in fibrotic diseases of the liver, lung and colon, etc. In this study, we firstly constructed FAP-CAR macrophages to target FAP+ cells through in vitro phagocytosis assays. In subsequent in vivo assays, we discovered that FAP-CAR-ΔZETA bone marrow-derived macrophages (BMDMs) rather than FAP-CAR BMDMs, exhibited a pronounced anti-tumor effect in mouse subcutaneous MC38 colon cancer model. In addition, FAP-CAR and FAP-CAR-ΔZETA BMDMs therapy could effectively improve CCl4-induced liver fibrosis in mice. Collectively, CAR-Ms targeting FAP demonstrated great therapeutic potential in cancer and liver fibrosis therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China. Electronic address: shengchj@sysucc.org.cn.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China. Electronic address: chenshuai@sysucc.org.cn.
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Mao, Y., Yao, C., Zhang, S., Zeng, Q., Wang, J., Sheng, C., & Chen, S. (2024). Targeting fibroblast activation protein with chimeric antigen receptor macrophages. Biochemical Pharmacology, 230, 116604. https://doi.org/10.1016/j.bcp.2024.116604
Vancouver
Mao Y, Yao C, Zhang S, Zeng Q, Wang J, Sheng C, et al. Targeting fibroblast activation protein with chimeric antigen receptor macrophages. Biochemical Pharmacology. 2024;230:116604. doi:10.1016/j.bcp.2024.116604
BibTeX
@article{Mao2024,
author = {Mao, Yizhi and Yao, Chen and Zhang, Shimeng and Zeng, Qi and Wang, Jing and Sheng, Chunjie and Chen, Shuai},
title = {Targeting fibroblast activation protein with chimeric antigen receptor macrophages},
journal = {Biochemical Pharmacology},
year = {2024},
volume = {230},
pages = {116604},
doi = {10.1016/j.bcp.2024.116604}
}
EUVIMED